Genetically Programmable Fusion Cellular Vesicles for Cancer Immunotherapy.

Area of Science:

• Immunology
• Biotechnology
• Oncology

Background:

• Cancer immunotherapy aims to harness the immune system against tumors.
• Immune checkpoints like CD47 and PD-L1 regulate immune responses and are often exploited by cancer cells.
• Developing targeted therapies that overcome immune evasion is crucial for effective cancer treatment.

Purpose of the Study:

• To engineer fusion cellular vesicles (Fus-CVs) for dual blockade of CD47 and PD-L1.
• To evaluate the efficacy of Fus-CVs in activating innate and adaptive antitumor immunity.
• To assess the therapeutic potential of Fus-CVs in preclinical cancer models.

Main Methods:

• Genetic engineering of cellular vesicles to display high-affinity SIRPα variants and PD-1.
• In vitro assessment of macrophage phagocytosis and antigen presentation.
• In vivo studies in malignant melanoma and mammary carcinoma models to evaluate tumor recurrence, metastasis, and survival.

Main Results:

• Fus-CVs effectively blocked CD47 and PD-L1, significantly increasing cancer cell phagocytosis by macrophages.
• Dual blockade activated antitumor T-cell immunity and promoted antigen presentation.
• Treatment with Fus-CVs significantly improved overall survival by inhibiting post-surgery tumor recurrence and metastasis in preclinical models.

Conclusions:

• Genetically programmable Fus-CVs represent a promising platform for multi-targeting immune checkpoint blockade therapy.
• The bispecific targeting of Fus-CVs enhances therapeutic efficacy while minimizing systemic side effects.
• Fus-CVs demonstrate significant potential for improving outcomes in various cancer types.